China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd has recently obtained clinical trial clearances for two of its products in China. The products are KQ-2003, an autologous chimeric antigen receptor (CAR) T cell therapy for the fourth-line treatment of recurrent/refractory multiple myeloma, and KY-0118, a therapy aimed at treating locally advanced or metastatic solid tumors.
KQ-2003: Next-Generation CAR-T Therapy for Multiple Myeloma
KQ-2003, which targets B cell maturation antigen (BCMA) and CD19, is set to commence Phase I clinical studies at Peking Union Medical College Hospital. This next-generation CAR-T therapy represents an advancement in the treatment of multiple myeloma, offering a potential new option for patients who have exhausted other lines of treatment.
KY-0118: Potential First-In-Class PD-1 Targeted Mutant IL-2 Fusion Protein
KY-0118, an in-house developed PD-1 targeted mutant IL-2 fusion protein, is a potential first-in-class molecule, second globally only to a similar molecule under development by Roche. This drug is being tested at the Chinese PLA General Hospital and has shown preliminary signs of good safety and efficacy, positioning it as a promising candidate for further development and potential commercialization.-Fineline Info & Tech
